Daniel Shevrin to Aged, 80 and over
This is a "connection" page, showing publications Daniel Shevrin has written about Aged, 80 and over.
Connection Strength
0.211
-
An item bank was created to improve the measurement of cancer-related fatigue. J Clin Epidemiol. 2005 Feb; 58(2):190-7.
Score: 0.030
-
Radium-223 in combination with docetaxel in patients with castration-resistant prostate cancer and bone metastases: a phase 1 dose escalation/randomised phase 2a trial. Eur J Cancer. 2019 06; 114:107-116.
Score: 0.020
-
Validating the total illness burden index for prostate cancer (TIBI-CaP) in men with castration-resistant prostate cancer: data from TRUMPET. Future Oncol. 2018 Mar; 14(6):527-536.
Score: 0.019
-
Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol. 2018 04 01; 36(10):991-999.
Score: 0.019
-
Seven-Month Prostate-Specific Antigen Is Prognostic in Metastatic Hormone-Sensitive Prostate Cancer Treated With Androgen Deprivation With or Without Docetaxel. J Clin Oncol. 2018 02 01; 36(4):376-382.
Score: 0.019
-
Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer. N Engl J Med. 2015 Aug 20; 373(8):737-46.
Score: 0.016
-
Phase I/II trial of orteronel (TAK-700)--an investigational 17,20-lyase inhibitor--in patients with metastatic castration-resistant prostate cancer. Clin Cancer Res. 2014 Mar 01; 20(5):1335-44.
Score: 0.014
-
Phase II trial of 6-thioguanine in advanced renal cell carcinoma. An Illinois Cancer Center study. Invest New Drugs. 1994; 12(4):345-6.
Score: 0.014
-
Efficient assessment of the most important symptoms in advanced prostate cancer: the NCCN/FACT-P Symptom Index. Psychooncology. 2011 Sep; 20(9):977-83.
Score: 0.011
-
Constructing a conceptual framework of patient-reported outcomes for metastatic hormone-refractory prostate cancer. Value Health. 2010 Aug; 13(5):613-23.
Score: 0.011
-
Phase II trial of fludarabine phosphate in advanced renal cell carcinoma: an Illinois Cancer Council Study. Invest New Drugs. 1989 Jul; 7(2-3):251-3.
Score: 0.010
-
Randomized, double-blinded phase II evaluation of docetaxel with or without doxercalciferol in patients with metastatic, androgen-independent prostate cancer. Clin Cancer Res. 2008 Apr 15; 14(8):2437-43.
Score: 0.009
-
Use of a single-item screening tool to detect clinically significant fatigue, pain, distress, and anorexia in ambulatory cancer practice. J Pain Symptom Manage. 2008 Jan; 35(1):20-30.
Score: 0.009
-
Longitudinal screening and management of fatigue, pain, and emotional distress associated with cancer therapy. Support Care Cancer. 2008 Feb; 16(2):151-9.
Score: 0.009